Ajanta Pharma’s record is clean on its face: eight years of unqualified audit opinions, no capital-market penalties, and a stable statutory auditor. Three things deserve attention. Receivables have ballooned to 125 days, driving operating cash flow down to half of reported profit. An August 2025 Income Tax search and block-period notice create an unquantified overhang. And four promoter-family members hold key board roles, with public institutional shareholders casting up to 29% dissent against their re-election.
Key findings
- Receivables ballooned to 125 days, driving cash flow to half of profit
Major- Consolidated receivables days rose to 125 in FY2026 from 94 in FY2025, which management attributes to a shift from factoring to working capital loans. Operating cash flow of ₹529 crore covered only 50% of reported profit of ₹1,056 crore, down from 126% coverage in FY2025. Revenue recognition has been a Key Audit Matter in every annual report from FY2019 through FY2026, with auditors citing fraud risk from pressure to meet targets. - An August 2025 tax search and block notice create an unquantified overhang
Major- Income Tax authorities searched Ajanta Pharma’s premises in August 2025, and on 6 February 2026 the company received a notice under Section 158BC requiring a return of undisclosed income for the block period 1 April 2019 to 17 November 2025. The company filed its return on 6 April 2026 reporting no undisclosed income, and the financial impact remains unascertainable as of the FY2025-26 annual report. The auditor’s report includes an Emphasis of Matter, a special call-out in the audit report, drawing attention to this unascertainable impact. - Promoter family dominates the board, and public institutions have dissented up to 29%
Major- The board has four members of the Agrawal promoter family: Mannalal B. Agrawal (Non-Executive Chairman), Madhusudan B. Agrawal (Executive Director & Vice-Chairman), Yogesh M. Agrawal (Managing Director), and Rajesh M. Agrawal (Joint Managing Director). At the FY2023 AGM, the resolution to re-appoint Mr. Madhusudan B. Agrawal received 29.03% votes against from public institutions. Promoter pledge stood at 22.53% of promoter holding in FY2026, up from 14.43% a year ago, with one pledge invocation of ₹96 crore recorded on 29 September 2023. - The tax search is a substantive enforcement action, though no capital-market penalties exist
Major- The August 2025 search and the block-assessment notice dated 6 February 2026 constitute a substantive regulatory enforcement action with unascertainable financial impact. The company’s corporate governance reports for FY2020-21 through FY2025-26 each state that no penalties were imposed by stock exchanges, SEBI, or any other statutory authority on capital-market matters. The Secretarial Compliance Report for FY2025-26 confirms no enforcement actions by SEBI or stock exchanges during the year. - Shareholder returns exceeded free cash flow in multiple years, and CWIP lacks ageing disclosure
Minor- Free cash flow fell 54% to ₹535 crore in FY2026 from ₹1,158 crore in FY2025. In FY2023, the company returned ₹479 crore to shareholders via dividend and buyback while free cash flow was ₹793 crore. Capital work-in-progress stood at ₹258 crore as of FY2026, with the FY2022 annual report stating projects are executed as per a rolling annual plan, without disclosing individual project ageing. - The statutory auditor has been stable since 2017, while the cost auditor resigned mid-term in May 2024
Minor- BSR & Co. LLP has been the statutory auditor since 5 July 2017 and was re-appointed on 4 August 2022 for a second five-year term until 2027. Cost auditor M/s. Sevekari Khare & Associates resigned on 2 May 2024, citing personal reasons and ineligibility to continue. M/s. RA & Co., Cost Accountants was appointed as the new cost auditor on the same day. - Prior-period tax adjustments and a failed land sale are small and disclosed
Clean- In FY2025, the company recognised a current tax benefit of ₹24.98 Crore for prior periods, comprising reversal of excess provision and a tax benefit under an amnesty scheme. In FY2026, the adjustment fell to a reversal of just ₹0.09 Crore. A freehold land asset of ₹8.85 Crore was reclassified from “Assets Held for Sale” back to “Property, Plant and Equipment” because the proposed sale was not concluded. - The subsidiary structure is stable, with legacy problem entities fully provided for
Clean- The group had five foreign subsidiaries as of 31 March 2026, including one new entity, Ajanta Pharma Ireland Limited, incorporated on 19 December 2025. The standalone company has made full provision for its investment in Ajanta Pharma Nigeria Limited, with carrying value considered Nil as of 31 March 2026. The step-down subsidiary Ajanta Pharma (Mauritius) International Limited was wound up on 27 September 2022 as part of tax-structure rationalisation.
What to watch
- Income Tax block assessment. The company filed its return for the block period 1 April 2019 to 17 November 2025 on 6 April 2026; the impact remained unascertainable as of the FY2025-26 Annual Report.
- Receivables and factoring. Watch for any reversion to factoring, given the stated shift to working capital loans in FY2026.
- Single customer concentration. Any change in the identity or credit quality of the customer contributing over 10% of Group revenue (₹730 crore in FY2026).
- CWIP conversion. Track the ₹258 crore capital work-in-progress for transfers to fixed assets or impairment, as the FY2026 annual report does not disclose project-level ageing or completion timelines.
- Disputed tax additions. Outcome of disputed income tax additions of ₹3.23 crore first recognised in FY2024-25.
- Patent litigations. Outcome of the two ongoing patent litigations as at 31 March 2026.
Bottom line: This is a disclosed and audited record with unqualified opinions and no capital-market penalties. The risk sits in three places: the 125-day receivables balance that halved cash conversion, the unquantified overhang from the August 2025 tax search, and a promoter-dominated board that has drawn material institutional dissent. Watch whether the block assessment yields a demand, and whether the receivables line normalises in FY2027.